These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18838439)

  • 1. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
    Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Guevremont C; Alasker A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):170-9. PubMed ID: 19528803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
    Ravaud A
    Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on systemic therapies of metastatic renal cell carcinoma.
    Herrmann E; Bierer S; Wülfing C
    World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
    Bhojani N; Jeldres C; Patard JJ; Perrotte P; Suardi N; Hutterer G; Patenaude F; Oudard S; Karakiewicz PI
    Eur Urol; 2008 May; 53(5):917-30. PubMed ID: 18054825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
    Cella D
    Oncologist; 2011; 16 Suppl 2(Suppl 2):23-31. PubMed ID: 21346037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
    J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
    P J G; A M; L M; H J H; M K; S B; N M
    Urol Oncol; 2014 Apr; 32(3):362-70. PubMed ID: 24321255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of targeted therapies for renal cell cancer].
    Merseburger AS; Kuczyk MA
    Urologe A; 2008 Oct; 47(10):1303-10. PubMed ID: 18587556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Fléchon A; Boyle H; Négrier S
    Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
    Schmidinger M; Zielinski CC
    Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
    Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.